Blood Loss in Women of Childbearing Potential Taking Oral Anticoagulants for Venous Thromboembolism (The BLEED Study)
Blutverlust bei Frauen im gebärfähigen Alter unter oralen Antikoagulanzien bei venöser Thromboembolie (BLEED-Studie)
Thrombosis and Haemostasis · 01.06.2025 · 125 (06) · 523-532
DOI: 10.1055/a-2461-6822 ↗Auf einen Blick
Bei 110 Frauen unter oralen Antikoagulanzien wegen venöser Thromboembolie veränderten sich Hb-Werte und PBAC-Scores während der Behandlung. Uterusmyome waren mit stärkeren Hb-Abnahmen und mehr ungeplanten Konsultationen verbunden.
Fragestellung
Untersucht wurde abnormales uterines Bluten bei Frauen im gebärfähigen Alter unter Vitamin-K-Antagonisten oder direkten oralen Antikoagulanzien wegen venöser Thromboembolie.
Methode
Retrospektive Analyse prospektiv erhobener Daten; Blutung mit PBAC und Hb-Werten vor und unter Antikoagulation bewertet; ungeplante Arztbesuche wegen Blutung erfasst. Rekrutierung von Juni 2014 bis November 2023.
Ergebnisse
110 Frauen, median 36 Jahre. PBAC korrelierte mit Hb zu Baseline und unter Therapie (ANOVA, p < 0,01); Hb-Unterschied vor vs. während Therapie zwischen Gruppen unterschiedlich (ANOVA, p 0,034).
Schlussfolgerung der Autor:innen
Frauen im gebärfähigen Alter unter oralen Antikoagulanzien zeigen während der Behandlung häufig Veränderungen von Hb-Werten und PBAC-Scores; Uterusmyome spielen dabei eine wichtige Rolle.
Kernaussagen
- 110 Frauen mit VTE unter OAC
- PBAC und Hb waren während der Therapie verändert
- Uterusmyome: mehr Hb-Abfall und mehr ungeplante Konsultationen
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.06.2025. Verfasst von Elvira Grandone und 6 weiteren Autor:innen. Beteiligte Einrichtung: Obstetrics and Gynaecology Department, University of Foggia, Foggia, Italy. Hauptthemen laut MEDLINE: Venous Thromboembolism, Anticoagulants, Uterine Hemorrhage. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: HORIZON EUROPE European Innovation Council, European Commission, HORIZON EUROPE Framework Programme.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Oral anticoagulants (OAC) may exacerbate menstrual bleeding in women of childbearing age; however, the existing literature on this issue has several limitations. This study investigates abnormal uterine bleeding in women of childbearing age taking OAC–vitamin K antagonists or direct oral anticoagulants–for venous thromboembolism through a retrospective analysis of prospectively collected data. Uterine bleeding was assessed using the Pictorial Blood Assessment Chart (PBAC) and hemoglobin (Hb) values during anticoagulation compared with prior therapy. The number of unplanned medical visits for bleeding complications was also calculated. From June 2014 to November 2023, 110 women were recruited (median age, 36 years). PBAC scores correlated with Hb values at baseline and during therapy (analysis of variance [ANOVA], p < 0.01), with a significant difference in Hb values before and during anticoagulant therapy (delta Hb) among groups (ANOVA, p.0.034). Seventeen women (15.5%) reported uterine fibroids, experiencing a greater reduction in Hb values during anticoagulant administration than women without uterine fibroids (delta 0.3, interquartile range [IQR]: 0.8, 2.9 vs. 0.5, IQR 1.2, 0.3; p.0.012). Women with selfreported uterine fibroids required more frequent unplanned medical consultations for bleeding (mean visits 5 vs. 4, respectively; Poisson regression, p < 0.05). Among women with uterine fibroids, those taking apixaban showed smaller Hb changes than those on other oral anticoagulants (ANOVA, p.0.047). This difference persisted even after adjusting for potential confounders (multiple ANOVA, p.0.004). Women of childbearing age taking OAC frequently experience changes in Hb values and PBAC scores during treatment, with uterine fibroids playing a significant role.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Obstetrics and Gynaecology Department, University of Foggia, Foggia, Italy.
- Thrombosis and Haemostasis Unit, Fondazione I.R.C.C.S. "Casa Sollievo della Sofferenza", S. Giovanni R., Foggia, Italy.
- Department of Obstetrics, Gynaecology and Perinatal Medicine, The First I.M. Sechenov Moscow State Medical University, Moscow, Russia.
- Scientific Direction, Fondazione I.R.C.C.S. "Casa Sollievo della Sofferenza", S. Giovanni R., Foggia, Italy.
- Department of Cardiology, University of Foggia, Foggia, Italy.
- Division of Cardiovascular Medicine and Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States.
ORCID-Profile: Elvira Grandone
Förderung
- HORIZON EUROPE European Innovation Council
- European Commission
- HORIZON EUROPE Framework Programme
- HORIZON EUROPE Innovative Europe
- Ministero della Salute
- Ricerca Corrente
Zitieren
APA
Grandone, E., Mastroianno, M., Pacilli, G., Colaizzo, D., Margaglione, A., Bikdeli, B., & Piazza, G. (2025). Blood Loss in Women of Childbearing Potential Taking Oral Anticoagulants for Venous Thromboembolism (The BLEED Study). Thrombosis and Haemostasis, 125(06), 523-532. https://doi.org/10.1055/a-2461-6822
Vancouver
Grandone E, Mastroianno M, Pacilli G, Colaizzo D, Margaglione A, Bikdeli B, et al. Blood Loss in Women of Childbearing Potential Taking Oral Anticoagulants for Venous Thromboembolism (The BLEED Study). Thrombosis and Haemostasis. 2025;125(06):523-532. doi:10.1055/a-2461-6822
BibTeX
@article{Grandone2025,
author = {Grandone, Elvira and Mastroianno, Mario and Pacilli, Gabriella and Colaizzo, Donatella and Margaglione, Alessandra and Bikdeli, Behnood and Piazza, Gregory},
title = {Blood Loss in Women of Childbearing Potential Taking Oral Anticoagulants for Venous Thromboembolism (The BLEED Study)},
journal = {Thrombosis and Haemostasis},
year = {2025},
volume = {125},
number = {06},
pages = {523--532},
doi = {10.1055/a-2461-6822}
}
EUVIMED